Prior immunity protective against severe outcomes of COVID-19 infections in children

The evolution of SARS-CoV-2 variants and increasing immunity altered the impact of pediatric SARS-CoV-2 infection. Reliable and accurate clinical information reporting is critical for effective public health decision-making.

The data of a recent study has confirmed that prior immunity protects against severe outcomes of SARS-CoV-2 infections in children, similar to adults. This study is published in The Pediatric Infectious Disease Journal.

This study was an international hospital-based multicenter prospective cohort study. The real-time reporting was active from March 2020 to December 2022. In this study, researchers evaluated longitudinal incident rates and risk factors for disease severity.

Key results of this study are:

  • Researchers included 564 hospitalized children with a history of acute COVID-19 in 375 children or multisystem inflammatory syndrome in children in 189 children from the Netherlands, Curaçao and Surinam.
  • In COVID-19, 134 patients, constituting 36%, needed supplemental oxygen therapy, and 35 patients, including 9.3 %, required intensive care treatment.
  • Predictors for severe COVID-19 included age above 12 years and preexisting pulmonary conditions.
  • During omicron, Hospitalized children had milder disease.
  • During population immunity, the incidence rate of pediatric COVID-19 infection declined for older children. It was stable for children below one year.
  • The incidence rate of multisystem inflammatory syndrome in children was highest during the delta wave. It decreased rapidly since omicron emerged.
  • Real-time reporting impacted national pediatric SARS-CoV-2 vaccination- and booster policies.

The COVID-19 pandemic has affected social and healthcare-related aspects worldwide. Healthcare decision-makers, medical staff, and hospital managers require reliable and updated information to make informed decisions.

The reporting framework of our consortium is readily accessible for future SARS-CoV-2 waves and other emerging infections, they said.

Study limitations include the observational nature of the study design, limited generalizability, reporting bias, etc.

Reference:

Tulling, Adam J. et al. Severe Pediatric COVID-19 and Multisystem Inflammatory Syndrome in Children From Wild-type to Population Immunity: A Prospective Multicenter Cohort Study With Real-time Reporting. The Pediatric Infectious Disease Journal.



from Medical News, Health News Latest, Medical News Today - Medical Dialogues | https://ift.tt/6r7KS3E

Comments

Post a Comment

Popular posts from this blog

'Details sought include Third-party info, hence exempted under RTI Act': NMC on RTI query on Faculty Gap in Medical Colleges

Image
New Delhi:  Stating that the details sought under the RTI includes third-party information, the National Medical Commission (NMC) has refused to disclose the names of the medical colleges that fell short on faculty counts and other teaching infrastructure. Recently activist Dr. KV Babu filed an application under the Right to Information Act seeking the details of the notices issued by the NMC Undergraduate Medical Education Board (UGMEB) to the medical colleges for deficiencies in Clinical Material and staff during the period from 01/01/2023 to 30/04/2024. He also sought to know the details of the fine imposed or the action taken by the NMC UG Board from 01/01/2023 to 30/04/2024. In response, the Apex medical regulatory body in India has said that the concerned information includes third party information. "Since the information sought by you, includes third party information, hence the same is exempted for as per Section 8(1) (j) of the Right to Information Act, 2005," th...
Read more

Intas Pharmaceuticals Gets CDSCO Panel Nod to Study Recombinant Human Follicle Stimulating Hormone

Image
New Delhi: Intas Pharmaceuticals has got approval from the Subject Expert Committee (SEC) functional under the Central Drug Standard Control Organisation (CDSCO) to conduct a Phase I clinical trial of the Recombinant Human Follicle Stimulating Hormone 300 IU Solution for Injection. However, this approval is subject to the condition that the firm should have tied up with an IVF center in case of an emergency. This came after the firm presented the protocol to conduct a Phase I clinical study of Recombinant Human Follicle Stimulating Hormone 300 IU Solution for Injection titled " An open label, Phase-I, balanced, randomized, two-treatment, two-period, two-sequence, single subcutaneous dose administration, crossover, bioequivalence study of r-h-FSH (recombinant human follicle stimulating hormone injection), solution for injection of Intas Pharmaceuticals Limited, India with Gonal-f, recombinant human follicle stimulating hormone (r-hFSH) follitropin alfa, solution for injection ...
Read more

ICMR invites proposals for Centre for Advanced Research under Extramural Research Program, Details

Image
New Delhi- Through a notice, the Indian Council of Medical Research (ICMR) has called for concept proposals for the Centre for Advanced Research (CAR), under the Extramural Research Program. The Last Date for concept proposal is November 21, 2024. Under its Extramural Research Programme, the Indian Council of Medical Research (ICMR) funds the Centre for Advanced Research (CAR) to promote advanced research by experienced research teams.   What the CAR is expected to do: Conducting decisive research that helps in solving an important healthcare problem by a research team. It can have single or multiple linked research projects with clear deliverables. It encourages in-depth research, to generate new knowledge and solutions for health problems in multiple aspects of causation, progression, management and prevention. Priority diseases or conditions: Research teams planning to undertake studies in finding solutions for prevention, screening, diagnosis, treatment or rehabilita...
Read more